Viking Therapeutics, Inc. (VKTX)
- Sector
- Biotechnology
- Last price
- $26.65
- As of
Kresmion compiles this page from VKTX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Viking Therapeutics, Inc. (VKTX): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-28.
See the full VKTX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for VKTX on one page. Preview it with sample data, then open it live with a free account.
Preview the VKTX dossierActive signals for VKTX
- highCONSENSUS_BUY
3 tracked funds increased VKTX this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +2391% to VKTX (2026Q2)
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +896% to VKTX (2026Q2)
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 67% of VKTX (2026Q2)
- highINSTITUTIONAL_EXIT
D. E. Shaw & Co., Inc. cut 96% of VKTX (2026Q2)
FREE, NO ACCOUNT
Every signal on VKTX, as it fires
You are seeing 5 of 11 signals recorded on VKTX since 2026-05-17.
The five above landed across 2 days. The other 6 were recorded on 3 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in VKTX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 92686J106 · 2026Q2 | $153.6M | 0.11% | , |
| D. E. Shaw & Co., Inc.CUSIP 92686J106 · 2026Q2 | $62.6M | 0.03% | , |
| CITADEL ADVISORS LLCCUSIP 92686J106 · 2026Q2 | $37.1M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 92686J106 · 2026Q2 | $19.4M | 0.01% | , |
| Point72 Asset Management, L.P.CUSIP 92686J106 · 2026Q2 | $18.5M | 0.02% | , |
| Bridgewater Associates, LPCUSIP 92686J106 · 2026Q2 | $3.4M | 0.01% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, VKTX
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
VKTX against its peers
VKTX's return on equity of -56.3% ranks in the 18th percentile of 24 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | VKTX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 0.0 USD | 179M USD | 5 | 18 |
| Operating margin | n/a | -72.8% | n/a | 17 |
| Net margin | n/a | -52.0% | n/a | 17 |
| Return on equity | -56.3% | -29.5% | 18 | 24 |
| 1 year | -21.4% | 33.3% | 8 | 19 |
Peers (24): LEGN, VCYT, XENE, IDYA, TLX, CPRX, ACAD, GRTX, RLAY, ARQT, CELC, TNGX, DNLI, DYN, EWTX, RCUS, ELVN, DNTH, ZLAB, PGEN, ATAI, TVTX, BEAM, DFTX. Left out: PBLS (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (VKTX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow VKTX on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to VKTX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.